JPRN-UMIN000041113已完成未知
A study evaluating effectiveness, safety, and pharmacokinetics of the Bictegravir/Emtricitabine/Tenofovir alafenamide single-tablet regimen in treatment-experienced elderly Japanese subjects living with HIV - A study of the Biktarvy targeting elderly Japanese subjects living with HIV.
ational Center for Global Health and Medicine0 个研究点目标入组 10 人开始时间: 2020年7月17日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 50years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)Liver cirrhosis (2)Concurrent medication which might interact with BIC, such as metformin (3)Patients whose physicians consider the study enrollment inappropriate.
研究者
相似试验
已完成
不适用
A multi-nutrient intervention for pregnant women experiencing symptoms of depression and anxiety.DepressionMental Health - DepressionReproductive Health and Childbirth - Normal pregnancyMental Health - AnxietyAnxietyACTRN12617000354381Professor Julia Rucklidge88
进行中（未招募）
1 期
A study to evaluate the efficacy, safety, and pharmacokinetics of IgPro20 in adults with dermatomyositis (DM)MedDRA version: 20.0Level: LLTClassification code 10001403Term: Adult dermatomyositisSystem Organ Class: 100000004858DermatomyositisEUCTR2018-003171-35-DECSL Behring LLC126
进行中（未招募）
1 期
A study to evaluate the efficacy, safety, and pharmacokinetics of IgPro20 in adults with dermatomyositis (DM)MedDRA version: 20.0Level: LLTClassification code 10001403Term: Adult dermatomyositisSystem Organ Class: 100000004858DermatomyositisEUCTR2018-003171-35-HUCSL Behring LLC126
进行中（未招募）
1 期
A study to evaluate the efficacy, safety, and pharmacokinetics of IgPro20 in adults with dermatomyositis (DM)MedDRA version: 20.0Level: LLTClassification code 10001403Term: Adult dermatomyositisSystem Organ Class: 100000004858DermatomyositisEUCTR2018-003171-35-ITCSL BEHRING GMBH126
已完成
3 期
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults with Dermatomyositis (DM) - The RECLAIIM StudydermatomyositisNL-OMON55228CSL Behring LLC